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Cystic Fibrosis (CF)
• Recessive genetic disorder
• Dysfunction of cystic fibrosis transmembrane
conductance regulator (CFTR) protein
• Regulates chloride
• Reduces viscosity of fluids

• Effects many organ systems

Naehrig S, et al. Dtsch Arztebl Int. 2017;114(33-34):564-574.

Pathophysiology
Normal

Kumar S, et al. Eur J Intern Med. 2014;25:803-807.

Mutation

Implications
Absorption

• Potentially reduced

Distribution

• Potentially less protein
• Protein-bound drugs are cleared faster à volume of distribution (Vd)
and clearance (CL) increased

Metabolism

• Unknown
• Potentially increased due to increased hepatobiliary blood flow

Excretion
Castagnola E, et al. Int J Antimicrob. 2021;106381.

• Variable depending on severity of illness, mutation type, etc.

Cystic Fibrosis Center
• CF Foundation recommends pharmacists participate in
patient care
• Complex disease state
• Interdisciplinary team required for proper patient care

https://www.cff.org/Research/Researcher-Resources/Patient-Registry/Cystic-Fibrosis-Foundation-Patient-Registry-Highlights.pdf

Assessment Question #1
Cystic fibrosis patients require specific medications and
drug dosing due to:
a) Additional genetic material at chromosome 21
b) Genetic mutation in the CFTR protein
c) Genetic mutation in the hemoglobin-Beta gene on
chromosome 11
d) Genetic mutation in the FBN1 gene
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Incidence – America
• Newborn screening estimates 1/4000 live births
• Previously most common life-threatening inherited
disorder in
Caucasians

https://www.cff.org/Research/Researcher-Resources/Patient-Registry/Cystic-Fibrosis-Foundation-Patient-Registry-Highlights.pdf

Incidence – Indiana
CF centers in IN:
1. St. Joseph Regional
Medical Center
2. Riley Hospital for
Children
3. Indiana University
Medical Center
4. Lutheran Hospital
5. Parkview Regional
Medical Center
https://www.cff.org/Research/Researcher-Resources/Patient-Registry/Cystic-Fibrosis-Foundation-Patient-Registry-Highlights.pdf

Impact on Healthcare
Fort Wayne

CF Registry

• Lutheran reported caring for • 31,199 patients in the
75-100 patients
registry in 2019 aged 12
and up
• 7-9 CF patients per day
seen in clinic 3 Mondays per
• 21,391 hospitalizations
month
• 34% of patients 12-17 years
old hospitalized at least
once in 2019

Cystic Fibrosis Foundation - Patient Registry Annual Data Report.

Relevance
• 74 pediatric beds in an
adult hospital
• Starting a pediatric CF
center – currently given
partial accreditation
• Focus on inpatient care
as pediatric
clinical specialist is not
24/7

Literature Review - Oncology
Objective

Methods

• To develop and
implement an
interdisciplinary oncology
program in a community
hospital

• Phase 1: Development of
guidelines and
references
• Phase 2: Development of
a patient-centered model
• Phase 3: Continuous
communication process

Chung C, et al. Am J Health-Syst Pharm. 2011;68:1740-1747.

Literature Review - Infectious Disease (ID)
Objective
• To describe implementation
of antimicrobial management
programs across a large
health system of community
hospitals

Burgess L, et al. Am J Infect Control. 2019;47:69-73. .

Methods
• Phase 1: Establish multidisciplinary team
• Phase 2: Formulary
evaluation & training
• Phase 3: Care optimization
phase & implementation
• Phase 4: Refining workflow
efficiency

Literature Review - Conclusions
Phased approach was central to success
Both received funding for a new pharmacist position
Saw cost savings and a reduction in errors
Lacked objective metrics
Chung C, et al. Am J Health-Syst Pharm. 2011;68:1740-1747.
Burgess L, et al. Am J Infect Control. 2019;47:69-73.

Assessment Question #2
A key area of implementing new pharmacy services is:
a)
b)
c)
d)

Improve marketing strategies
Evaluate insurance coverage
Provide education to staff
Increase ordering of medications
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Purpose & Methods
• Prepare pharmacy for inpatient treatment of CF patients

1

2

3

Create appropriate
protocols and order
sets to care for CF
patients

Provide staff
pharmacists with
appropriate training
& resources

Create & manage
the electronic
support needed
within our institution

Implementation Timeline
August 2021

October 2021

Meet with important stakeholders

Primary literature search to verify correct
dosing, duration, and frequency of
antibiotics for use in cystic fibrosis

• Nurse Practitioner
• Pediatric pulmonologist

Finish admission order set

Verify home medication policy
Begin literature search

September 2021

Order Sets - Admission
• Cultures – sputum, acid-fast bacilli (AFB)
• Inhaled medications
•
•
•
•

Albuterol
Dornase alfa
Hypertonic saline
Antibiotics

• Vitamins
• Salt supplementation

Home Medications
Automatically use home supply
• Pancreatic enzymes
• Fat-soluble vitamins (ADEK)
• Cystic fibrosis transmembrane conductance regulator (CFTR)
modulators

Policy – Patients’ Own Supply
Policy – Formulary

Implementation Timeline
November 2021

January 2022

Took antibiotic dosing recommendations to
important stakeholders to get feedback

Worked with order set team to create
intravenous (IV) antibiotic order set
Began literature search regarding CF
pharmacokinetics

• Changes made
• Conversations about extended-infusion beta-lactams

Antibiotic dosing approved by important
stakeholders
Antibiotic order set draft sent to order set
team

December 2021

Order Set Creation
• Owned by one of the service lines
• Service line designates a medical content expert
• Develop and approve clinical content
• Obtain feedback and consensus from other service lines
• Responsible for ensuring evidence-based practice

• Approved by all stakeholders
• Order set sent to electronic health record (EHR) team for
build

Order Sets – Antibiotics (IV)
• Includes:
• Beta-lactams, aminoglycosides, fluoroquinolones, tetracyclines
• Others à clindamycin, linezolid, sulfamethoxazole-trimethoprim,
vancomycin

• Considerations:
• Extended-infusion dosing
• Cefepime, ceftazidime, meropenem, nafcillin
• Piperacillin-tazobactam

• Safety for other pediatric patients

Other Project Considerations
ID Restrictions
• Ceftaroline
Therapeutic Interchange
• Ciprofloxacin
IV Pumps
• Extended-infusion dosing

Order Sets – Antibiotics (oral)
• Includes:
• Beta-lactams, fluoroquinolones, tetracyclines
• Others à azithromycin, clindamycin, ethambutol, linezolid,
rifampin, rifabutin, sulfamethoxazole-trimethoprim

• Considerations:
• Oral tablets, capsules, and suspensions
• Set doses based on weight/age

Implementation Timeline
February 2022

April 2022

Draft aminoglycoside, vancomycin, and
antibiotic (IV and oral) protocol for
pharmacy to dose consults

Implement protocol & educate pharmacy
team
Close other loose ends

Finalize protocol and take to formulary
subcommittee
Create pharmacist education to roll out
before protocol goes live

March 2022

Cystic Fibrosis Protocol
• Consult placed by provider for pharmacy to dose
• Antibiotic chosen by provider
• 3-in-1 pharmacy protocol
Aminoglycosides
• Recommended
initial dosing
• Goal peak and goal
time undetected
• Recommended lab
monitoring

Vancomycin
• Recommended
initial dosing
• Goal trough
• Recommended lab
monitoring

Antibiotics
• Same dosing as
available in the
order set
• Includes both IV
and oral

Aminoglycoside Kinetics
• Pharmacokinetic equations
• Parkview pharmacists familiar with utilizing nomogram for
extended-infusion dosing in adults
• How to calculate peak and time level is undetectable based on
2- and 6-hour random levels
• Guidance with examples in protocols

• Pharmacokinetic spreadsheet
• Aminoglycoside kinetics calculations
• Input patient specific data à new dose/frequency guidance

Education for Pharmacists
• Online slide presentation
• Basics of cystic fibrosis
• Disease progression
• Medications à what, why, how

• Competency quiz
• Content questions
• Pharmacokinetic scenarios

• Announcements once project components are active

Challenges
• Previous protocols/policies
• Coordination between:
• Pharmacy and providers
• Pharmacy and EHR team

• Timeline implementation

Future Directions
Implement oral antibiotic order set
Integrate pharmacy into outpatient clinic
Publish process and findings

Conclusions
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